We seek mechanism-based tools to identify, classify, treat, and monitor kidney disease. Our short-term goal is to improve the quantity and quality of clinical trials. Our long-term goal is to adjust therapies in individual patients to maximize efficacy and minimize toxicity.
We leverage the synergy between pathophysiology, therapeutics, and biomarkers to advance our understanding of acute and chronic kidney disease. We refine animal models to mimic disease characteristics identified in the clinic, especially by epidemiological studies.
Applying our Research
Need for Further Study
Our current understanding of the series of events that drive chronic kidney disease and acute kidney injury comes from animal models, but their ability to predict how well therapies will work in human patients is limited. In the animal models, we can get very detailed information about the disease that is not possible in patients. Therefore, noninvasive biomarkers may be the best bridge between animal models and patients, and they need to be developed and validated extensively.